Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | PEPIDH1M vaccine + Vorasidenib |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
PEPIDH1M vaccine | PEPIDH1M | PEPIDH1M vaccine is a peptide vaccine based on isocitrate dehydrogenase 1 (IDH1) harboring the R132H point mutation, which may induce a host immune response against tumor cells expressing IDH1 R132H (NCI Drug Dictionary). | ||
Vorasidenib | Voranigo | AG-881|AG881 | IDH Inhibitor (Pan) 3 | Voranigo (vorasidenib) inhibits both mutant IDH1 and IDH2, thereby inhibiting cell proliferation in tumors expressing mutant IDH (PMID: 27292784, PMID: 32071674). Voranigo (vorasidenib) is FDA-approved for use in adult and pediatric patients 12 years and older with IDH-mutant grade 2 astrocytoma or oligodendroglioma following surgery (FDA.gov) |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05609994 | Phase I | PEPIDH1M vaccine + Vorasidenib | ViCToRy: Vorasidenib in Combination With Tumor Specific Peptide Vaccine for Recurrent IDH1 Mutant Lower Grade Gliomas (ViCToRy) | Not yet recruiting | USA | 0 |